Company intelligence / Profile preview

Exxel Pharma

Aurora, Colorado, United Statesexxelpharma.com ↗
Ownership
Private
Development stage
Other
01

Overview

Exxel Pharma’s lead program, EX937, is a first-in-class oral small molecule FAAH inhibitor designed to treat refractory chronic cough by increasing anandamide levels and reducing neuronal hypersensitivity. Preclinical data show efficacy in models of cough, neuropathic pain, migraine, and hyperactive bladder with a favorable safety profile and peripheral action that avoids CNS side effects. The company is preparing for its first-in-human Phase 1/1b study in late 2025.

Therapeutic areas
PulmonologyPsychiatryNeurologyNephrology
Modalities
Small molecule
Industry
Biotech
02

Drug pipeline

2 assets

EX14280

Preclinical

1 more asset in the full pipeline.

Request access →
03

Partnerships

Exxel signed a sponsored research agreement with a large pharma company for its peripheral neuropathic pain therapeutic in November 2020terms for outlicensing the ARN program were finalized in March 2021

Beyond the preview

Go deeper on Exxel Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exxel Pharma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call